No Safety Shortcuts Under Breakthrough Designation, Synthetic Biologics Finds

Synthetic Biologics emerged from meetings with US FDA without its breakthrough designation, but with hope that agency will allow decoupling of safety and efficacy endpoints in planned Phase III trial for prevention of C. difficile infection.